Author + information
- Jalal K. Ghali, MD, FACC, FACP* ()
- ↵*LSU Health Sciences Center, Cardiology Section, 1501 Kings Highway, Shreveport, LA 71130
According to the important report by Rouleau et al. (1) and the thoughtful accompanying editorial by Cohn (2), one would expect heart-failure patients with the lowest systolic blood pressure, and who are at the highest risk because of the severity of heart failure, to enjoy a higher relative benefit from carvedilol compared to patients with higher systolic blood pressure. Would the investigators speculate on why the relative benefit was similar across all pretreatment systolic blood pressure levels?
- American College of Cardiology Foundation
- Rouleau J.L.,
- Roecker E.B.,
- Tendera M.,
- et al.
- Cohn J.N.